Business Wire

MultiSafepay joins Ant International’s Antom to Enhance Digital Payments Services for SMEs in Europe

1.7.2024 16:12:00 EEST | Business Wire | Press release

Share

MultiSafepay (MSP), an Amsterdam-based payment service provider, and Antom global merchant payment services (Antom), a leading payment and digitization services provider under Ant International, announced today that MultiSafepay has become a wholly-owned subsidiary of Ant International and will integrate with Antom to promote convenient, secure and accessible payment solutions and digitalization services to businesses, especially small and medium-sized enterprises (SMEs) across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701540843/en/

Olaf Geurs, CEO of MultiSafepay (left) and Gary Liu, General Manager of Antom Global (right), in a ceremony. (Photo: Business Wire)

MultiSafepay now serves merchants with omnichannel payment services connecting over 40 international payment methods, including cards, e-wallets, Buy-Now, Pay-Laters, internet banking, and more. Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. In addition to flexible, secure and reliable payment options, Antom brings a suite of marketing and digitalization services to empower local and regional businesses with more growth opportunities.

Through this strategic partnership, MultiSafepay will leverage Antom’s cutting edge technology and digital capabilities to further expand its product offerings and SME merchant coverage in the region.

Since 1999, MultiSafepay has been a pioneer simplifying payment for SME businesses. It provides world-class payment solutions to over 18,000 SMEs, empowering them to concentrate on their business while MSP optimizes payment success rates, payment handling and processing combined with a personal approach.

Olaf Geurs, CEO of MultiSafepay said, “The past 25 years have been an incredible journey. Together with our amazing team, we've bootstrapped MultiSafepay into a leading full-service PSP in Europe, overcoming countless obstacles along the way. The entrepreneurial spirit never sleeps, which is why we're partnering with Antom to unlock even greater growth potential for MultiSafepay's products and services, attracting even more businesses to our ecosystem.”

Gary Liu, General Manager of Antom Global said, “We are thrilled to join hands with MultiSafepay, a trusted industry innovator and our long-term partner. SMEs are the pillar of regional and global prosperity. With digital innovations, we look forward to building together more secure, flexible and efficient payment solutions with cross-sector partners, for small businesses to thrive in a truly inclusive and sustainable global commerce ecosystem.”

About MultiSafepay

MultiSafepay is a leading Netherlands-based payment services provider using cutting-edge in-house-developed technology to help businesses of all sizes focus on growth and innovation. It offers European companies a simple, tailored payments ecosystem for online, in-person, and omnichannel solutions through a single platform and integration. MultiSafepay offers a personal approach to payments, optimizing payment success rates and reducing complexities to allow businesses and platforms to concentrate and drive their growth.

About Antom

Ant International’s Antom is a leading provider of payment and digitization services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitization services to help merchant in digital operations and to better engage with their customers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701540843/en/

Contacts

Media contact:
Ant International
Fanny Wu
chen.wc@antgroup.com

Ant International
Joshua Way
joshua.way@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye